Genetic Susceptibility to Cervical Cancer
宫颈癌的遗传易感性
基本信息
- 批准号:6931120
- 负责人:
- 金额:$ 34.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-08-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:cervix neoplasmsclinical researchfamily geneticsfemalegene frequencygenetic markersgenetic screeninggenetic susceptibilityhuman genetic material taghuman papillomavirushuman subjectlinkage disequilibriumsneoplasm /cancer geneticsphlebotomyquestionnairesserotypingsingle nucleotide polymorphismvirus related neoplasm /cancer
项目摘要
DESCRIPTION (provided by applicant): Cervical cancer kills more than 200,000 people each year worldwide, disproportionately affecting women of low socioeconomic status. Infection with high-risk human papillomavirus (HPV) is the main causal factor, but additional factors must be involved because only a small proportion of HPV-infected women develop cancer. Epidemiologic studies suggest that some predisposing factors are genetic heritability accounts for about 27 percent of the total variation in liability to cervical tumor development. Because the responsible genes (or gene variants) have not been uncovered, it is not yet possible to develop methods for identifying the small proportion of women with preinvasive cervical intraepithelial neoplasia (CIN) who will need treatment. To address this deficit, we plan to identify markers that associate with cervical cancer. Such markers might also be useful for screening women in the general population. To elucidate the role of genetic factors in the development of cervical cancer, we will study DNA from women who have invasive cervical cancer (ICC) or CIN III and are also infected with high risk HPV subtypes. We will select candidate genes that appear critical for the development of the cancer, including the HLA DQB1/DRB1 locus and other immune markers, genes that are cellular targets of HPV E6, E7, and E5 oncoproteins, and genes implicated in the progression of cervical neoplasia. Within each gene, we will focus on small variations, such as differences in single bases. Such single nucleotide polymorphisms (SNPs) are the most common genetic variations among individuals, accounting for a substantial proportion of phenotypic variability. We will evaluate their influence on interactions between HPV and cervical cells by using the transmission/disequilibrium test (TDT). Unlike the case-control method, the TDT assesses associations between specific alleles and disease endpoints without being vulnerable to errors caused by stratification of genetically disparate populations or undiagnosed preclinical disease in "controls.'" We will test each variation for association with ICC or CIN Ill by comparing frequency distributions of patient alleles (cases) with those of nontransmitted parental 'alleles, which provide a perfect ethnically matched control sample. If a polymorphism is inherited with higher-than-Mendelian frequency by the women with ICC or CIN III, we will suspect that variant of predisposing HPV-infected women to cervical cancer. Subsequent case control and cohort studies could then confirm the association. This investigative sequence is much more cost-effective than population studies that begin without first identifying potentially culpable genes. Determining how small variations in host DNA influence vulnerability to cervical cancer is critical to understanding the pathogenesis of the disease and therefore to the development of superior screening and diagnostic tests. As the field of pharmacogenetics expands, this information might enable vaccine and drug developers to tailor their products to "cervical cancer genotypes."
描述(由申请人提供):全世界每年有超过20万人死于子宫颈癌,其中社会经济地位较低的妇女所受影响尤为严重。感染高危人乳头瘤病毒(HPV)是主要的致病因素,但必须涉及其他因素,因为只有一小部分感染HPV的妇女会患上癌症。流行病学研究表明,一些易感因素是遗传因素,约占宫颈癌发展总变异的27%。由于相关基因(或基因变异)尚未被发现,因此尚不可能找到方法来识别一小部分需要治疗的宫颈浸润前上皮内瘤变(CIN)妇女。为了解决这一缺陷,我们计划确定与宫颈癌相关的标志物。这些标记也可能对筛查普通人群中的女性有用。为了阐明遗传因素在宫颈癌发展中的作用,我们将研究浸润性宫颈癌(ICC)或CIN III型妇女的DNA,这些妇女也感染了高危HPV亚型。我们将选择对癌症发展至关重要的候选基因,包括HLA DQB1/DRB1位点和其他免疫标记,HPV E6、E7和E5癌蛋白的细胞靶点基因,以及与宫颈肿瘤进展有关的基因。在每个基因中,我们将关注微小的变异,例如单个碱基的差异。这种单核苷酸多态性(SNPs)是个体之间最常见的遗传变异,占表型变异的很大一部分。我们将通过传播/不平衡试验(TDT)评估它们对HPV与宫颈细胞相互作用的影响。与病例对照法不同,TDT评估特定等位基因和疾病终点之间的关联,而不容易受到“对照组”中遗传差异人群分层或未诊断的临床前疾病引起的错误的影响。“我们将通过比较患者等位基因(病例)与未传播的亲本等位基因的频率分布来测试每个变异与ICC或CIN的关联,这提供了一个完美的种族匹配的对照样本。”如果患有ICC或CIN III的妇女遗传的多态性高于孟德尔频率,我们将怀疑这种变异使hpv感染的妇女易患宫颈癌。随后的病例对照和队列研究可以证实这种关联。这种调查顺序比不首先确定潜在的有罪基因就开始的人口研究更具成本效益。确定宿主DNA的微小变异如何影响对宫颈癌的易感性,对于了解该疾病的发病机制,从而开发更好的筛查和诊断测试至关重要。随着药物遗传学领域的扩展,这些信息可能使疫苗和药物开发商能够根据“宫颈癌基因型”定制他们的产品。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janet S. Rader其他文献
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
鲁比替康和吉西他滨治疗晚期恶性肿瘤患者的 I 期研究。
- DOI:
- 发表时间:
2002 - 期刊:
- 影响因子:50.5
- 作者:
P. Fracasso;Janet S. Rader;R. Govindan;Thomas J. Herzog;M. Arquette;Alex E. Denes;D. Mutch;J. Picus;B. Tan;C. L. Fears;S. A. Goodner;S. Sun - 通讯作者:
S. Sun
The mons pubis: An excellent graft donor site in gynecologic surgery
- DOI:
10.1016/0002-9378(90)90994-i - 发表时间:
1990-03-01 - 期刊:
- 影响因子:
- 作者:
Michelle R. Dudzinski;Janet S. Rader - 通讯作者:
Janet S. Rader
Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
预防性疫苗时代的宫颈癌预防:妇科肿瘤学家的预览。
- DOI:
- 发表时间:
2006 - 期刊:
- 影响因子:4.7
- 作者:
Y. Collins;M. Einstein;B. Gostout;Thomas J. Herzog;L. Stuart Massad;Janet S. Rader;J. Wright - 通讯作者:
J. Wright
Role of the ultrasonic surgical aspirator in gynecology.
超声手术吸引器在妇科中的作用。
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:3.2
- 作者:
Neil S. Horowitz;Janet S. Rader - 通讯作者:
Janet S. Rader
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer
贝伐珠单抗治疗复发性卵巢癌毒性和疗效预测因素的多机构评估
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Jason Wright;A. Secord;T. Numnum;R. Rocconi;M. Powell;Andrew Berchuck;Ronald D. Alvarez;R. Gibb;Kathryn Trinkaus;Janet S. Rader;D. Mutch - 通讯作者:
D. Mutch
Janet S. Rader的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janet S. Rader', 18)}}的其他基金
Early Career-CeNtered EnricHment to AdvaNce Research Careers in Maternal HEalth -ENHANCE-M
以早期职业为中心的丰富活动,以推进孕产妇健康领域的研究职业 -ENHANCE-M
- 批准号:
10756021 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Enlisting HPV integration events to illuminate drivers and target treatment in invasive cervical cancer
招募 HPV 整合事件来阐明浸润性宫颈癌的驱动因素和靶向治疗
- 批准号:
10666600 - 财政年份:2022
- 资助金额:
$ 34.04万 - 项目类别:
Defining HPV integration sites of unknown significance in invasive cervical cancer
定义浸润性宫颈癌中意义不明的 HPV 整合位点
- 批准号:
10042465 - 财政年份:2020
- 资助金额:
$ 34.04万 - 项目类别:
PROTEOMIC BIOMARKER PROFILING OF CERVICAL SWABS
宫颈拭子的蛋白质组生物标志物分析
- 批准号:
8361413 - 财政年份:2011
- 资助金额:
$ 34.04万 - 项目类别:
PROTEOMIC BIOMARKER PROFILING OF CERVICAL SWABS
宫颈拭子的蛋白质组生物标志物分析
- 批准号:
8168817 - 财政年份:2010
- 资助金额:
$ 34.04万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 34.04万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:














{{item.name}}会员




